Table 1 Characteristics and miR-128 expression in breast cancer patients
From: MiR-128 suppresses metastatic capacity by targeting metadherin in breast cancer cells
| Factors |
Patients Number (%) |
log
(fold repression of miR−128)2
(mean ± SEM) | P value |
|---|---|---|---|
| Age(year) | 0.137a | ||
| ≤ 50 | 13 (39.39%) | − 2.74 ± 1.20 | |
| > 50 | 20 (60.61%) | − 5.53 ± 1.24 | |
| Tumor size(cm) | 0.279a | ||
| ≤ 3 | 20 (60.61%) | − 3.63 ± 1.02 | |
| > 3 | 13 (39.39%) | − 5.68 ± 1.70 | |
| Grade | 0.025a | ||
| II | 14 (42.42%) | − 2.09 ± 0.79 | |
| III | 19 (57.58%) | − 6.16 ± 1.36 | |
| TNM stage | 0.639b | ||
| Ι | 4 (12.12%) | − 2.57 ± 1.49 | |
| ΙΙ | 22 (66.67%) | − 5.02 ± 1.23 | |
| ΙΙΙ | 7 (21.21%) | − 3.66 ± 1.72 | |
| ER status | 0.711b | ||
| Strongly positive | 13 (39.39%) | − 5.23 ± 1.64 | |
| Mildly positive | 8 (24.24%) | − 3.24 ± 1.45 | |
| Negative | 12 (36.37) | − 4.37 ± 1.55 | |
| PR status | 0.879b | ||
| Strongly positive | 6 (18.18%) | − 4.62 ± 2.89 | |
| Mildly positive | 11 (33.33%) | − 5.02 ± 1.47 | |
| Negative | 16 (48.49%) | − 3.96 ± 1.26 | |
| HER2 status | 0.817b | ||
| Strongly positive | 9 (27.27%) | − 4.17 ± 2.21 | |
| Mildly positive | 20 (60.61%) | − 4.25 ± 1.08 | |
| Negative | 4 (12.12%) | − 5.97 ± 2.36 | |
| MIB | 0.805a | ||
| ≤ 20% | 15 (45.45%) | − 4.18 ± 1.39 | |
| > 20% | 18 (54.55%) | − 4.65 ± 1.24 | |
| Node status | 0.821a | ||
| Positive | 15 (45.45%) | − 4.20 ± 1.31 | |
| Negative | 18 (54.55%) | − 4.63 ± 1.30 |